A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by activating the mother’s immune system to produce defence proteins, which are then passed to the foetus through the placenta. This mother-derived protection offers newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence indicating that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85 per cent protection when immunised four weeks before birth
- Maternal antibodies passed through placenta protect newborns from birth
- Protection achievable with two-week gap before early delivery
- Vaccination in the third trimester still offers meaningful protection for infants
Compelling evidence from recent research
The performance of the pregnancy RSV vaccine has been demonstrated through a extensive research programme carried out throughout England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month timeframe, providing robust and representative data of the vaccine’s actual performance. The study’s results have been supported by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The scope of this study provides healthcare professionals and expectant parents with trust in the vaccine’s proven efficacy across different groups and contexts.
The results reveal a striking picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This clear distinction underscores the vaccine’s critical role in reducing the risk of serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The sizeable sample and thorough nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology captured real-world outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine performs when given across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and the hazards
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for vulnerable newborns to feed and breathe properly. Parents frequently observe their babies struggling visibly, their chests rising whilst they try to pull sufficient oxygen into their damaged lungs. Whilst the majority of babies get better with clinical support, a limited though important number die from respiratory syncytial virus complications yearly, making immunisation programmes a critical public health objective for safeguarding the youngest and most vulnerable individuals in the population.
- RSV triggers lung inflammation, causing severe breathing difficulties in babies
- Approximately half of infants contract the virus in their first few months of life
- Symptoms span from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV annually
- A small number of babies succumb to RSV complications each year in the UK
Uptake rates and expert recommendations
Since the RSV vaccine programme began in 2024, health officials have emphasised the significance of pregnant women receiving their jab at the best time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns receive the most robust immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery delivers approximately 85% protection, experts recommend women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies through the placenta.
The messaging from health authorities stays clear: pregnant women should prioritise vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of serious illness.
Regional differences in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Certain regions have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to increase awareness and access to the jab. These geographical variations reflect variations in healthcare infrastructure, communication strategies, and local engagement efforts, though the overall statistics demonstrates consistently strong protection regardless of geographical location.
- NHS trusts launching varied communication campaigns to engage with women during pregnancy
- Geographic variations in vaccination coverage levels throughout England necessitate strategic intervention
- Regional health providers adapting programmes to align with local requirements and situations
Practical implications and parental perspectives
The vaccine’s impressive effectiveness delivers concrete gains for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the launch of this protective measure, the 80% drop in admissions means thousands of infants spared from severe infection. Parents no longer face the upsetting situation of watching their newborns labour to breathe or labour to feed, symptoms that mark serious RSV disease. The vaccine has substantially transformed the picture of neonatal lung health, offering expectant mothers a proactive tool to protect their most vulnerable children during those crucial first weeks.
For families like that of Malachi, whose acute RSV infection led to severe brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s advocacy for the jab underscores the life-altering consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now given protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to expectant mothers in their final trimester, transforming what was once an unavoidable seasonal threat into a controllable health concern.